Nasal spray reverses brain aging in mice for months
Just two doses of a nasal spray improved memory and cognitive function in aging mice for several months.
Researchers at Texas A&M University developed the spray by combining an anti-inflammatory compound with a molecule that supports mitochondrial function in brain cells. Mitochondria are the energy-generating structures inside cells, and their gradual decline is a well-documented feature of brain aging. Chronic low-grade neuroinflammation is the other side of the same coin.
The nasal route was chosen deliberately. Drugs delivered through the nose can reach the brain directly, bypassing the blood-brain barrier. That barrier blocks most candidate drugs from reaching neural tissue, which has long been a central problem in developing treatments for dementia and cognitive decline.
Two doses, months of benefit
The researchers report that treated mice outperformed controls in memory tests, and the effect persisted for months after just two administrations. Crucially, targeting both inflammation and mitochondrial dysfunction together produced better results than addressing either alone. The combination appears to be key.
The study has not yet been replicated in humans, and mouse models of brain aging do not always translate. That caveat matters. Still, the underlying mechanisms, neuroinflammation and mitochondrial decay, are well established in human dementia research and represent validated targets.
What this means for dementia research
The practical appeal is real. A nasal spray is non-invasive and easy to administer, including in elderly patients who struggle with injections or complex medication regimens. Researchers are careful to note that dementia involves multiple overlapping processes, and no single intervention addresses all of them.
What makes this approach notable is the dual-target design. Treating neuroinflammation and mitochondrial decline simultaneously reflects a growing consensus in the field: aging-related brain disease requires combination strategies, not single-pathway fixes.